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Frontotemporal dementia (FTD) is a genetically and pathologically heterogeneous 
disorder characterized by personality changes, language impairment, and deficits of 
executive functions associated with frontal and temporal lobe degeneration. Different 
phenotypes have been defined on the basis of presenting clinical symptoms, i.e., the 
behavioral variant of FTD, the agrammatic variant of primary progressive aphasia, and 
the semantic variant of PPA. Some patients have an associated movement disorder, 
either parkinsonism, as in progressive supranuclear palsy and corticobasal syndrome, or 
motor neuron disease (FTD–MND). A family history of dementia is found in 40% of cases 
of FTD and about 10% have a clear autosomal-dominant inheritance. Genetic studies 
have identified several genes associated with monogenic FTD: microtubule-associated 
protein tau, progranulin, TAR DNA-binding protein 43, valosin-containing protein, 
charged multivesicular body protein 2B, fused in sarcoma, and the hexanucleotide 
repeat expansion in intron 1 of the chromosome 9 open reading frame 72. Patients often 
present with an extensive phenotypic variability, even among different members of the 
same kindred carrying an identical disease mutation. The objective of the present work 
is to review and evaluate available literature data in order to highlight recent advances 
in clinical, biological, and neuroimaging features of monogenic frontotemporal lobar 
degeneration and try to identify different mechanisms underlying the extreme phenotypic 
heterogeneity that characterizes this disease.
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introduction
Frontotemporal dementia (FTD) is the second most common cause of dementia in the presenile 
age group (<65 years of age), and accounts for 5–15% of all cases of dementia, with a prevalence of 
10–15 per 100,000 subjects in the age group of 45–65 years (Bird et al., 2003; Feldman et al., 2003; 
Borroni et al., 2015b).
Frontotemporal dementia is a genetically and pathologically heterogeneous disorder character-
ized by personality changes, language impairment, and deficits of executive functions, associated 
with frontal and temporal lobe degeneration (The Lund and Manchester Groups, 1994; Neary et al., 
1998; McKhann et al., 2001).
Current redefined clinical criteria recognize different phenotypes on the basis of presenting 
clinical symptoms, namely the behavioral variant of FTD (bvFTD), the agrammatic variant of 
primary progressive aphasia (avPPA), and the semantic variant of PPA (svPPA) (Mesulam, 1982; 
Gorno-Tempini et al., 2011; Rascovsky et al., 2011). Moreover, some patients have an associated 
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parkinsonism, as in progressive supranuclear palsy (PSP) and 
corticobasal syndrome (CBS), or motor neuron disease (FTD–
MND) (Lomen-Hoerth et al., 2002; Burrell et al., 2011; Armstrong 
et al., 2013).
A family history of dementia is found in 25–50% of cases of 
FTD and about 10% have a clear autosomal-dominant inherit-
ance (Seelaar et  al., 2008; Rohrer et  al., 2009). Genetic studies 
have identified several genes associated with monogenic FTD: 
in 1998, mutations in the microtubule-associated protein tau 
(MAPT) gene on chromosome 17 were identified in families with 
FTD and parkinsonism (Hutton et al., 1998; Poorkaj et al., 1998; 
Spillantini et al., 1998). In spite of this finding, there have been 
numerous reports of families with linkage to chromosome 17q21 
but without evidence of MAPT pathogenic mutations (Froelich 
et al., 1997; Kertesz et al., 2000; Rosso et al., 2001; Rademakers 
et al., 2002).
In 2006, the second FTD-related gene on chromosome 17 was 
discovered in the progranulin (GRN) gene (Baker et  al., 2006; 
Cruts et al., 2006), accounting for even more cases than mutations 
in MAPT explaining all the 17q21-linked autosomal-dominant 
FTD cases not accounted for by MAPT mutations (www.molgen.
ua.ac.be/ADMutations/).
Eventually, a genetic linkage to a locus on chromosome 9p 
was found in many families with FTD and motor neuron disease 
(Morita et al., 2006; Vance et al., 2006; Luty et al., 2008; Le Ber 
et al., 2009; Boxer et al., 2011); only recently in 2011, two separate 
groups identified the defect as being an expanded hexanucleotide 
repeat in a non-coding region of the chromosome 9 open reading 
frame 72 (C9orf72) gene (DeJesus-Hernandez et al., 2011; Renton 
et al., 2011).
Other uncommon mutations have been identified in the valo-
sin-containing protein (VCP) gene, which cause inclusion body 
myopathy with Paget disease of bone and FTD (Watts et al., 2004), 
and in the charged multivesicular body protein 2B (CHMP2B) 
gene, involved in the endosomal–lysosomal pathway (Skibinski 
et al., 2005). Few reports have also described FTD associated with 
mutations in the fused in sarcoma (FUS) (Broustal et al., 2010; 
Van Langenhove et al., 2010), dynactin (DCTN1) (Münch et al., 
2005), sequestosome 1 (SQSTM1) (Fecto et  al., 2011; Rubino 
et al., 2012; van der Zee et al., 2014), colony-stimulating factor 
1 receptor (CFS1R) (Münch et al., 2005; Guerreiro et al., 2013b), 
triggering receptor expressed on myeloid cells (TREM2) (Borroni 
et  al., 2013; Guerreiro, 2013), ubiquilin-2 (UBQLN2) (Gellera 
et al., 2013), and heterogeneous nuclear ribonucleoprotein A2B1 
(hnRNPA2B1) genes (Kim et al., 2013).
Clinical FTD is associated with different types of under-
lying neuropathology, and the term frontotemporal lobar 
degeneration (FTLD), characterized by the relative selective 
degeneration of the frontal and temporal lobes, is used to 
describe the pathological hallmarks of the disease. Abnormal 
intracellular accumulation of insoluble proteins have been 
identified with immunohistochemical techniques and, 
according to the predominant neuronal inclusions, FTLD 
cases have been categorized into several types (Mackenzie 
et  al., 2008, 2010). At first, neuronal and glial inclusions of 
hyperphosphorylated tau protein were identified in FTLD-
tau, which represent nearly 30–40% of FTLD cases, and are 
found in patients carrying MAPT gene mutations, as well as 
in Pick’s disease, PSP, and corticobasal degeneration (CBD) 
(Josephs et al., 2006).
Only briefly after the discovery of the GRN gene, TAR DNA-
binding protein 43 (TDP-43) inclusions were identified as the 
predominant hallmark of the originally identified ubiquitin 
positive inclusions, which were termed FTLD-U (Mackenzie 
et al., 2006), and subsequently renamed FTLD-TDP (Arai et al., 
2006; Neumann et al., 2006). TDP-43 inclusions have also been 
identified in the majority of amyotrophic lateral sclerosis (ALS) 
and FTD-MND cases, in particular in patients with mutations of 
the C9orf72 gene. Four FTLD-TDP subtypes (A–D) have been 
proposed based on the location of these inclusions (Mackenzie 
et al., 2011).
Finally in 2009, the ~10% of FTLD cases negative for tau or 
TDP-43 pathology were characterized by inclusions immunore-
active for FUS, which were then labeled as FTLD-FUS (Munoz 
et  al., 2009; Neumann et  al., 2009b; Rademakers et  al., 2009). 
Furthermore, the inclusions positive for FUS were found to also 
stain for other members of the FET family of DNA/RNA-binding 
proteins, comprising the TATA-binding protein-associated factor 
15 (TAF-15) and Ewing sarcoma protein (EWS), distinguish-
ing FTLD with FUS pathology from ALS with FUS mutations 
(Neumann et al., 2011).
Patients with monogenic FTD often present with an extensive 
phenotypic variability, even among different members of the 
same kindred carrying an identical disease mutation.
The objective of the present work is to review and evaluate 
available literature data in order to highlight recent advances 
in clinical, biological, and neuroimaging features of monogenic 
FTLD and try to identify the hallmarks of different monogenic 
FTDs.
MAPT Mutations
The MAPT gene on chromosome 17, encoding the tau protein, was 
the first gene identified in families with FTD and parkinsonism 
(Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998). 
Tau is a natively unfolded protein that is abundantly expressed in 
the central nervous system where it regulates microtubule assem-
bly and stabilization, being involved in signal transduction and 
axonal transport (Goedert et al., 1989b). Forty-four pathogenic 
mutations in the MAPT gene have been identified so far (Cruts 
et al., 2012), causing the accumulation of hyperphosphorylated 
tau protein in neurons and glial cells (Hutton et al., 1998).
Alternative mRNA splicing of exons 2, 3, and 10 of the 
MAPT gene leads to the assembly of six tau isoforms that 
are expressed in the adult human brain (Neve et  al., 1986; 
Goedert et  al., 1989a; Andreadis et  al., 1992). The tau iso-
forms differ from each other by the presence or absence of a 
29-aminoacid or 58-aminoacid insert in the amino-terminal 
half and by the inclusion or not of a 31-aminoacid repeat 
encoded by exon 10 of MAPT in the carboxy-terminal half of 
the protein. The inclusion or exclusion of exon 10 results in 
the production of three isoforms with four repeats each (4R) 
or three isoforms with three repeats each (3R), respectively 
(Spillantini and Goedert, 2013). These repeats comprise the 
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microtubule-binding domains of tau, with 4R tau having 
greater predisposition for microtubule assembly than 3R tau 
(Goedert and Jakes, 1990).
Mutations can be differentiated into missense mutations in 
exons 9–13, influencing the normal function of the tau protein in 
microtubule stabilization, and intronic and some coding muta-
tions modifying the splicing of exon 10 at the mRNA level, result-
ing in a disproportionate ratio of 3R/4R tau isoforms (Goedert 
et al., 1989a).
The frequency of MAPT gene mutations is highly variable, 
ranging from 0–3% in sporadic FTD to 5–20% in familial cases 
(Houlden et  al., 1999; Rizzu et  al., 1999; Poorkaj et  al., 2001; 
Binetti et  al., 2003; Rademakers et  al., 2004; Kaivorinne et  al., 
2008; Pickering-Brown et al., 2008).
Heterogeneous clinical phenotypes with high penetrance 
(van Herpen et  al., 2003) have been observed in patients with 
mutations in the MAPT gene, even in families bearing the same 
pathogenic mutation (Van Swieten et  al., 1999; Janssen et  al., 
2002; Boeve et al., 2005).
Disease onset is also highly variable, ranging between 45 and 
65 years, with a mean age of onset of 55 years, nearly 10 years 
earlier than in patients with GRN mutations (Van Swieten and 
Spillantini, 2007). The disease may however occasionally present 
between 20 and 30  years (Van Swieten and Spillantini, 2007; 
Momeni et al., 2010) or after 70 years in a few mutations (Hayashi 
et al., 2002). The mean disease duration is 9 years, ranging from 
5 to 20 years (Seelaar et al., 2011).
The clinical phenotype of patients with MAPT mutations can 
be divided into a dementia-dominant type and a parkinsonism-
dominant type. The most common presentation, as with GRN 
mutations, is bvFTD, characterized by behavioral inhibition, 
impaired social behavior, and obsessive–compulsive disorder 
(Van Swieten and Spillantini, 2007). As with GRN mutations, 
patients may subsequently present parkinsonism, which rarely 
is the exclusive clinical presentation, and more often develops 
in association with bvFTD (Van Swieten and Spillantini, 2007; 
Rohrer et al., 2011b). However, some patients have a primary par-
kinsonian syndrome as in CBS or, more rarely, as in PSP (Dickson 
et  al., 2007; Van Swieten and Spillantini, 2007). Parkinsonian 
features consist of symmetrical bradykinesia, postural instability 
and rigidity affecting axial and appendicular musculature, absence 
of resting tremor, and poor or no responsiveness to levodopa 
(Ghetti et al., 2015). In patients carrying the N279K mutation, 
parkinsonism is an early feature and asymmetric resting tremor 
and levodopa responsiveness have been observed (Tsuboi et al., 
2002). Numerous other motor signs and symptoms have been 
observed, comprising supranuclear gaze palsy, upper and lower 
motor neuron dysfunction, dystonia, myoclonus, postural and 
action tremor, apraxia of eyelid opening and closing, dysphagia, 
and dysarthria (Ghetti et al., 2015).
Patients may also develop language impairment, which usu-
ally is not a presenting feature (Seelaar et al., 2008; Rohrer et al., 
2010b); indeed the P301L mutation was recently observed in a 
family with impaired single word comprehension suggestive of 
verbal semantic impairment (Ishizuka et al., 2011), and the V363I 
and G304S mutations have been reported in cases with avPPA 
(Munoz et al., 2007; Villa et al., 2011).
As with GRN mutations, there is no clear correlation between 
the type of mutation and the clinical presentation; however, anec-
dotal observations suggest that exonic mutations that do not affect 
the splicing of exon 10 are usually associated with a dementia-
predominant phenotype, and that intronic and exonic mutations 
that affect exon 10 splicing, leading to an overproduction of 4R 
tau, tend to be associated with a parkinsonism-predominant 
phenotype (Ghetti et al., 2015).
In some cases, episodic memory impairment has been observed 
in patients with MAPT mutations, in particular in the R406W 
mutation, mimicking Alzheimer’s disease (AD) (Tolboom et al., 
2010), or in the recently described duplication of the MAPT gene, 
where the predominant memory impairment was preceded by 
clinical symptoms characteristic of bvFTD (Rovelet-Lecrux et al., 
2010).
Neuroimaging studies have observed heterogeneous pat-
terns of cortical atrophy, but with predominant involvement of 
the frontal and temporal lobes, with occasional involvement of 
the parietal lobes (Van Swieten et al., 1999; Janssen et al., 2002; 
Boeve et al., 2005; Ghetti et al., 2008; Whitwell et al., 2009a,b). The 
atrophy is particularly prominent in the anteromedial temporal 
lobes (Spina et al., 2008; Whitwell et al., 2009a,c; Rohrer et al., 
2010b), with some studies showing that anteromedial atrophy 
is a feature of early stages of disease (Boeve et al., 2005). In the 
majority of individuals, patterns of cortical atrophy are relatively 
symmetrical (Van Swieten et al., 1999; Ghetti et al., 2008; Rohrer 
et al., 2011a); however, asymmetry has been observed in some 
cases (Boeve et al., 2005).
Atrophy of the basal ganglia and of the brainstem have been 
observed in studies on individual patients, possibly correlating 
with the parkinsonian features frequently associated with the 
disease (Arima et al., 2000; Soliveri et al., 2003; Slowinski et al., 
2009).
In spite of the fact that temporal lobe atrophy is the most 
typical finding in patients with MAPT mutations, the pattern of 
cortical atrophy can differ depending on the specific mutation. 
Indeed MAPT mutations affecting the splicing of exon 10 are 
mainly associated with medial temporal atrophy, while muta-
tions in the coding region are primarily associated with lateral 
temporal lobe atrophy (Whitwell et al., 2009a; Ghetti et al., 2015). 
These findings, if confirmed in other cohorts of subjects, could 
help identifying the underlying MAPT mutation.
As in structural imaging, functional imaging with F-18 fluoro-
deoxyglucose positron emission tomography (FDG-PET) often 
shows reduced frontal and/or temporal hypometabolism, which 
resembles the patterns observed in sporadic FTD (Frank et al., 
2007).
As in GRN mutations, structural imaging changes can be iden-
tified years before expected onset of symptoms in asymptomatic 
adults at risk of genetic FTD. Rohrer et al. observed differences, 
between MAPT mutation carriers and non-carriers, in the hip-
pocampus and amygdala 15 years before expected onset, followed 
by the temporal lobe 10 years before expected onset, and in the 
insula 5 years before expected onset (Rohrer et al., 2015b).
Functional connectivity in the default mode network (DMN) 
is altered in MAPT subjects before the occurrence of both atrophy 
and clinical symptoms, suggesting that changes in functional 
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connectivity are early features of the disease. Asymptomatic MAPT 
subjects show reduced connectivity in the DMN predominantly 
between precuneus and lateral temporal lobe, but also medial 
prefrontal cortex, compared to age-matched controls (Whitwell 
et al., 2011a). Significantly decreased fractional anisotropy (FA) 
and increased radial diffusivity in bilateral uncinate fasciculi 
and reduced FA in the forceps minor have also been observed in 
asymptomatic MAPT carriers (Dopper et al., 2014).
A preliminary study with the F-18-T807 PET ligand for tau in 
a patient carrying a MAPT mutation has demonstrated a classic 
frontotemporal distribution characteristic of inherited tauopa-
thies (Ghetti et al., 2015). These ligands, which characterize tau 
pathology in vivo (Fodero-Tavoletti et al., 2011; Xia et al., 2013), 
will undoubtedly improve our future understanding of the patho-
genesis of disorders characterized by tau deposition (Villemagne 
et al., 2015).
GRN Mutations
Since 2006, 69 distinct pathogenic mutations have been identified 
in the GRN gene, accounting for up to 20% of familial and 5% of 
sporadic FTD cases (Cruts et  al., 2012). Progranulin, which is 
expressed in many cell types, including neurons and microglia, 
is a secreted growth factor known for its role in biological pro-
cesses, including cellular and tissue development, inflammation, 
wound healing, and cancer, and for its neurotrophic properties. 
It is proteolytically processed into peptides called granulins, the 
function of which, in the nervous system, is still largely specula-
tive (Bateman and Bennett, 2009).
Almost all pathogenic mutations cause disease by haploin-
sufficiency (Baker et al., 2006; Cruts et al., 2006), reducing the 
levels of progranulin in cerebrospinal fluid, plasma, and serum in 
symptomatic and asymptomatic GRN mutation carriers (Ghidoni 
et al., 2008; Finch et al., 2009; Sleegers et al., 2009). Indeed, the 
measurement of plasmatic progranulin levels is now largely used 
to screen patients for GRN sequencing (Schofield et  al., 2010; 
Almeida et al., 2013).
A number of factors that influence progranulin expression 
have been identified in patients carrying GRN mutations. Genetic 
variants in TMEM106B (Van Deerlin et al., 2010), a gene encoding 
for the still uncharacterized transmembrane protein 106B, seem 
to delay the onset of disease in GRN mutation carriers, perhaps 
increasing the levels of progranulin (Cruchaga et al., 2011; Finch 
et al., 2011; van der Zee et al., 2011). Granulin expression is also 
regulated by microRNAs, including miR-29b and miR-107 (Jiao 
et al., 2010; Wang et al., 2010), and by sortilin (SORT1), a receptor 
for neurotrophic factors, which mediates progranulin endocyto-
sis and regulates the plasmatic levels of progranulin (Carrasquillo 
et al., 2010; Hu et al., 2010).
The clinical presentation in patients with GRN mutations is 
highly variable, and phenotypic heterogeneity can be observed in 
the same family carrying an identical pathogenic mutation (Beck 
et al., 2008; Gabryelewicz et al., 2010; Yu et al., 2010; Chen-Plotkin 
et al., 2011), with an age-dependent and incomplete penetrance 
(Cruts and Van Broeckhoven, 2008). Age at symptom onset var-
ies significantly, ranging from 35 to 89 years, with an average of 
65 years, and a penetrance of 50% by the age of 60 and 90% by 
the age of 70 years (Gass et al., 2006; van Swieten and Heutink, 
2008; Le Ber, 2013).
Within families, there is considerable variation in the age of 
onset, with a difference of up to 20  years between consecutive 
generations (Seelaar et al., 2008; van Swieten and Heutink, 2008). 
Neither age of disease onset nor the duration of the disease seems 
to have any correlation with the type or location of the GRN 
mutation.
The initially reported and most common clinical diagnosis in 
patients carrying GRN mutations is bvFTD, with significant apa-
thy and social withdrawal (Baker et al., 2006; Cruts et al., 2006). In 
addition, subsequent studies identified, at onset, a clinical presen-
tation characterized by aphasic disorders consistent with avPPA 
(Snowden et al., 2006; Mesulam et al., 2007; Le Ber et al., 2008), 
or CBS (Masellis et  al., 2006). The aphasic disorder associated 
with GRN mutations seems nevertheless to be distinct from the 
avPPA with apraxia of speech observed occasionally in patients 
with FTLD-tau (Rohrer et  al., 2010a,c), or from the logopenic 
variant of PPA (lvPPA), commonly associated with an atypical 
presentation of AD pathology (Gorno-Tempini et  al., 2011; 
Rohrer et al., 2012).
Extrapyramidal features have been reported in about 40% of 
patients with GRN mutations and include CBS with limb apraxia, 
asymmetrical parkinsonism, and dystonia, although they are 
rarely a primary symptom and usually emerge after the onset 
of behavioral or language symptoms (Yu et al., 2010), and only 
occasionally respond to levodopa (Carecchio et al., 2009; Di Fabio 
et al., 2010).
In almost 25% of patients hallucinations and delusions can be 
predominant, frequently causing a misdiagnosis of dementia with 
Lewy bodies (DLB) (Le Ber et  al., 2008; Kelley et  al., 2010; Yu 
et al., 2010).
Furthermore, an AD-like phenotype can be observed in 
patients with episodic memory deficit, which occurs in 10–30% 
of cases, or with parietal deficits, such as dyscalculia, visuospatial 
symptoms, and limb apraxia. This phenotype can be occasionally 
associated with the c.154delA mutation in GRN (Kelley et  al., 
2010) or with the genetic variant rs5848, where the minor T 
allele, located in the 3′-untranslated region of GRN, was found 
to increase the binding of miR-659 to GRN (Brouwers et  al., 
2008; Rademakers et al., 2008; Lee et al., 2011; Sheng et al., 2014), 
consequently reducing serum progranulin levels (Hsiung et al., 
2011).
A recent meta-analysis studied the association between the 
GRN polymorphism rs5848 and risk of neurodegenerative dis-
eases, including FTLD, AD, Parkinson’s disease (PD), and ALS, 
concluding that rs5848 was associated with an increased risk of 
AD and PD in the homozygous and recessive models but not with 
FTLD (Chen et al., 2015).
Since GRN mutations are associated with FTD-TDP pathol-
ogy, which is frequently observed also in ALS and FTD-ALS, it 
prompted the search for GRN mutations in patients with associ-
ated motor neuron disease. One study identified a missense 
mutation in a patient with FTD-ALS (p.S120Y) and in a single 
case of limb onset sporadic ALS (p.T182M) (Schymick et  al., 
2006), while a later study identified clinical features compatible 
with MND in 5.4% of patients carrying a GRN mutation; in this 
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cohort, concomitant motor neuron disease was much more com-
mon in patients with FTD-TDP pathology not bearing a GRN 
mutation (26.3%) (Chen-Plotkin et al., 2011).
Recently, it has been shown that a complete GRN deficiency 
due to a homozygous GRN loss-of-function mutation causes the 
rare lysosomal storage disease neuronal ceroid lipofuscinosis 
(Smith et al., 2012). These findings suggest that lysosomal stor-
age disorders and GRN-associated FTLD may share common 
features (Götzl et al., 2014).
Neuroimaging studies have highlighted that patients carrying 
a GRN mutation are more likely to show a pronounced asym-
metrical atrophy (Huey et  al., 2006; Bronner et  al., 2007; Beck 
et al., 2008; Pickering-Brown et al., 2008) affecting either the left 
or right hemispheres, involving primarily the inferior frontal 
(Bronner et al., 2007; Beck et al., 2008; Ghetti et al., 2008), tem-
poral and inferior parietal lobes (Mesulam et al., 2007; Pickering-
Brown et al., 2008), as well as long intrahemispheric association 
white matter (WM) tracts (Borroni et  al., 2008; Rohrer and 
Warren, 2011). A prominent feature, which is unusual in FTLD, is 
the predominance of parietal involvement (Whitwell et al., 2007; 
Beck et al., 2008; Le Ber et al., 2008), recently confirmed also in 
presymptomatic mutation carriers (Rohrer et  al., 2008, 2015b; 
Cruchaga et al., 2009). These findings have been also confirmed 
by voxel-based morphometry (VBM) studies, which detected a 
widespread and severe pattern of gray matter loss predominantly 
affecting the frontal, temporal, and parietal lobes (Whitwell et al., 
2009b, 2012). Along with cortical involvement, atrophy of deep 
subcortical structures has been identified in patients carrying 
GRN mutations, in particular in the caudate nucleus and in the 
thalamus bilaterally, possibly correlating with the parkinsonian 
features that are frequently associated since the early stages of the 
disease (Premi et al., 2014b).
Furthermore, cerebellar atrophy can be observed in some 
cases (Nuytemans et al., 2007; Benussi et al., 2008).
Subcortical WM involvement, ranging from T2-weighted 
MRI hyperintensities (Nuytemans et al., 2007; Le Ber et al., 2008; 
Kelley et al., 2009) to widespread WM lesions may be linked to 
progranulin pathological processes in a subset of GRN mutation 
carriers (Caroppo et al., 2014).
Annualized rates of whole brain atrophy, and consequently of 
ventricular expansion, are greatest in GRN, followed by sporadic 
FTD, C9ORF72, and lastly MAPT (Whitwell et  al., 2015), in 
which similar rates of hippocampal atrophy have been observed 
(Whitwell et al., 2011b).
Using single photon emission computed tomography 
(SPECT), hypoperfusion of the hippocampus and that of the 
cingulate gyrus have been observed, denoting the association of 
these regions with the pathogenesis of GRN mutations (Le Ber 
et al., 2008).
Recent studies have highlighted that structural imaging and 
cognitive changes can be identified years before expected onset 
of symptoms in asymptomatic adults at risk of genetic FTD. In 
the study by Rohrer et  al., in the GRN group, differences were 
observed between carriers and non-carriers in the insula at 
15 years before expected onset, then in the temporal and parietal 
lobes at 10 years before expected onset, with the earliest subcorti-
cal area affected being the striatum at 5  years before expected 
onset. GRN mutation carriers also showed significantly greater 
asymmetry than non-carriers at 5  years before expected onset 
(Rohrer et al., 2015b).
In functional connectivity studies, Premi et  al. observed in 
asymptomatic carriers of the GRN Thr272fs mutation, decreased 
brain connectivity within the left frontoparietal network and 
increased connectivity in the executive network compared with 
healthy controls (Premi et al., 2013b; 2014a). Furthermore, the 
TMEM106B at-risk polymorphism (T/T) was associated with 
decreased connectivity within the ventral salience network (i.e., 
middle frontal gyrus) and the left frontoparietal network (i.e., left 
precuneus) (Premi et al., 2013a). Further studies have confirmed 
the patterns of brain atrophy and WM tract abnormalities in 
frontal-parietal circuits and within the uncinate fasciculus, sup-
porting the hypothesis that WM damage is an early feature in the 
FTD disease process and can be detected at least a decade before 
the estimated symptom onset in asymptomatic mutation carriers 
(Dopper et al., 2014; Pievani et al., 2014).
C9orf72 Mutations
The strong association between FTD and ALS has become 
increasingly apparent due to a rapidly expanding body of clinical, 
epidemiological, genetic, and molecular evidence (Gros-Louis 
et al., 2006) and, in 2006, a locus was mapped on chromosome 
9p21 in FTD-ALS families (Vance et al., 2006). Until 2011, despite 
numerous efforts, the disease mutation remained elusive (Momeni 
et al., 2006; Morita et al., 2006; Valdmanis et al., 2007; Luty et al., 
2008; Le Ber et al., 2009; Boxer et al., 2011; Pearson et al., 2011). 
Eventually, DeJesus-Hernandez and colleagues observed the non-
Mendelian inheritance of a GGGGCC hexanucleotide repeat, 
located in a non-coding region of the C9orf72 gene, in the large 
VSM-20 family (Vancouver, San Francisco and Mayo family 20) 
affected by FTD-ALS, with the intuition that the repeat expansion, 
which was identified in the parents but not in the affected children 
by using fluorescent PCR, was too large to be amplified by the 
PCR method and could only be identified by repeated-primed 
PCR assay and Southern blot analysis (DeJesus-Hernandez et al., 
2011). With the use of next-generation sequencing, another 
group independently recognized the repeat expansion in a Welsh 
family affected by FTD-ALS (Renton et al., 2011).
Until recently, C9orf72 was a completely uncharacterized 
protein with unknown function. The pathogenesis underlying 
the C9orf72 mutation still remains unclear, but likely includes 
haploinsufficiency through loss of gene expression (Gijselinck 
et al., 2012; Cruts et al., 2013; van der Zee et al., 2013), gain-
of-function mechanisms with secondary RNA toxicity caused 
by sequestration of RNA-binding proteins (DeJesus-Hernandez 
et al., 2011; Lagier-Tourenne et al., 2013), or both (Rohrer et al., 
2015a).
Two different protein isoforms of the C9orf72 gene are predicted 
to be generated from a total of three different transcripts variants, 
depending on the localization of the GGGGCC repeat, either in 
the promoter or in the intron 1 of the gene (DeJesus-Hernandez 
et  al., 2011). All three different transcripts have been found to 
be reduced in blood (Mori et al., 2013a; Davidson et al., 2014), 
cortex, cerebellum, and spinal cord (Belzil et al., 2013; Donnelly 
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et al., 2013). This reduced expression possibly reflects, to a limited 
extent, the hypermethylation of a CpG island upstream of the 
repeat (Xi et  al., 2013; Belzil et  al., 2014; Liu et  al., 2014), and 
the methylation of lysine residues on H3 and H4 histones, which 
bind the GGGGCC repeats and suppress transcription (Xi et al., 
2013; Davidson et al., 2014; Russ et al., 2014), acting as a possible 
innate protective mechanism (Liu et  al., 2014; McMillan et  al., 
2015; Xi et al., 2015).
As previously mentioned, the neuropathological hallmarks, 
associated with C9orf72 mutations, are the TDP-43 immunore-
active inclusions, i.e., subtypes A and B (Mahoney et al., 2012; 
Lashley et al., 2014), which have been observed in many cerebral 
structures, including the extramotor cerebral cortex, hippocam-
pus, basal ganglia, substantia nigra, and lower motor neurons 
of the brainstem and spinal cord (Rademakers et  al., 2012). In 
addition to the TDP-43 pathology, a distinctive and singular 
feature is the presence of abundant TDP-43 negative, p62-positive 
inclusions, with a unique star-like morphology, in the cerebellum, 
hippocampus, and frontal cortex (Al-Sarraj et al., 2011; Simon-
Sanchez et al., 2012; Snowden et al., 2012; Troakes et al., 2012; 
Mori et al., 2013b).
Recently, Mori and colleagues tried to characterize these inclu-
sions, speculating that they may consist of dipeptide repeat (DPR) 
proteins which are the result of the bidirectional translation of the 
non-coding GGGGCC expansion repeat through a mechanism 
of non-ATG-initiated translation, termed RAN translation (Mori 
et  al., 2013c). Indeed, the researchers demonstrated that the 
GGGGCC expansion is bidirectionally translated into five dis-
tinct DPR proteins (Mori et al., 2013c), which have been observed 
in high load in neocortical regions, hippocampus, cerebellum 
and, to some extent, in motor neurons (Mackenzie et al., 2013). 
Moreover, the recent observation, in a Belgian C9orf72 carrier, 
of neuropathological aggregates of a DPR core surrounded 
by TDP-43 inclusions, suggested that DPR aggregation due 
to RAN translation could be the initial pathological event that 
possibly precedes and potentially triggers TDP-43 accumulation 
(Mackenzie et al., 2013; Mori et al., 2013c; van der Zee and Van 
Broeckhoven, 2014).
These findings have led to the suggestion that C9orf72 expan-
sion cases should be reclassified, from a neuropathological 
prospective, as FTLD-DPR, since identified cases can fit into one 
of two FTLD-TDP subtypes (A or B), or might even lack TDP-43 
pathology (Snowden et al., 2012; Mori et al., 2013c).
Despite these new findings implicating both loss-of-function 
and gain-of-function mechanism with new insights into the roles 
of sense (GGGGCC) and antisense (GGCCCC) repeat RNA and 
DPR proteins, the relative contribution to these mechanisms and 
the molecular pathways that lead to neurodegeneration are yet to 
be elucidated (Rohrer et al., 2015a).
The number of repeat units of the C9orf72 expansion in 
affected patients can range from at least several hundred to thou-
sands of copies, whereas unaffected healthy controls harbor 2–24 
repeat units (DeJesus-Hernandez et al., 2011; Beck et al., 2013; 
van Blitterswijk et al., 2013). So far, there is no clear evidence for 
intergenerational anticipation, although some studies have iden-
tified earlier disease onset in subsequent generations (Stewart 
et al., 2012; Benussi et al., 2014).
Whilst it is now rather clear that expansions of several hundred 
copies are definitely pathogenic, it is not known which is the small-
est hexanucleotide expansion that can confer a risk of developing 
the disease. Indeed, in vitro studies have demonstrated an inverse 
correlation between repeat size and gene expression starting at 
just 9 repeats, with a reduction of up to 50% in expression for 24 
expansion repeats (van der Zee et al., 2013).
Furthermore, as in other non-coding repeat expansion 
disorders, evidence for somatic instability of the C9orf72 repeat 
has been observed (DeJesus-Hernandez et  al., 2011), resulting 
in a range of mutation sizes in particular tissues with variation 
between tissues in the same individual. This possibly suggest that 
intermediate repeats detected in blood-sample-derived DNA 
might be associated with massive expansions in the brain (Rohrer 
et  al., 2015a), making it even harder to determine correlations 
between genetics, phenotype, and neuropathology (Lavedan 
et al., 1993; Matsuura et al., 2004). Indeed, a recent study tried 
to estimate, with Southern blotting techniques and densitometry, 
the repeat size of the most abundant GGGGCC expansion species 
in patients with ALS and FTD-ALS. Comparing different tissues, 
substantial variation in repeat sizes between samples from the 
cerebellum, frontal cortex, and blood have been identified. In 
particular, longer repeat sizes in the cerebellum seem to be associ-
ated with a survival disadvantage, indicating that expansion size 
does affect disease severity (Majounie et al., 2012).
As with GRN mutations, TMEM106B has been identified as a 
genetic modifier also in C9orf72 cases, demonstrating a signifi-
cantly later age at death and age at onset for the rs1990622 major 
allele (T) carriers (Gallagher et al., 2014).
Since the discovery of the C9orf72 mutation, testing of patients’ 
cohorts worldwide has found an average frequency of the patho-
genic expansion in 37% of familial ALS, 6% of sporadic ALS, 
21% of familial FTD, and 6% of sporadic FTD. Epidemiological 
studies have all established that the C9orf72 mutation is the major 
genetic cause of familial ALS (more frequent than superoxidose 
dismutase 1 mutations), and comparable in frequency to GRN 
mutations in familial FTD cases (DeJesus-Hernandez et al., 2011; 
Renton et al., 2011; Chiò et al., 2012; Hsiung et al., 2012; Majounie 
et al., 2012; Cruts et al., 2013; van der Zee et al., 2013).
Age at disease onset is widely variable, ranging from 27 to 
83 years (mean 50 years), with about 50% patients affected by age 
60 and with a penetrance reaching 90% at age 70. Disease duration 
is also variable, ranging from 1 to 22 years, with the development 
of ALS as a strong negative prognostic factor (Boeve et al., 2012; 
Chiò et  al., 2012; Cooper-Knock et  al., 2012; Gijselinck et  al., 
2012; Hsiung et al., 2012; Stewart et al., 2012).
Clinical phenotype is highly heterogeneous and variable 
even within families affected by the same mutation. The most 
common clinical presentations are FTD (Boeve et  al., 2012; 
Dobson-Stone et al., 2012; Englund et al., 2012; Hsiung et al., 
2012; Mahoney et  al., 2012; Sha et  al., 2012; Snowden et  al., 
2012; Devenney et  al., 2014), ALS (Boeve et  al., 2012; Byrne 
et al., 2012; Chiò et al., 2012; Cooper-Knock et al., 2012; Stewart 
et  al., 2012; Coon et  al., 2013; Montuschi et  al., 2015), or the 
combination of both. The most frequent FTD subtype is bvFTD, 
with avPPA observed less frequently, although other phenotypes 
have been described, and even cases with classical bvFTD or 
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ALS have extensive phenotypic heterogeneity. bvFTD associated 
with the C9orf72 mutation may present with classical features, as 
apathy, disinhibition, socially inappropriate behavior, abnormal 
eating behavior, and loss of empathy (Rascovsky et  al., 2011). 
Nevertheless, behavioral changes with features of psychosis, 
including hallucinations and delusions, are not rarely observed 
in these patients (Arighi et al., 2012; Boeve et al., 2012; Dobson-
Stone et  al., 2012; Englund et  al., 2012; Mahoney et  al., 2012; 
Snowden et  al., 2012; Galimberti et  al., 2013; Kertesz et  al., 
2013; Devenney et  al., 2014), and can even predominate at 
disease onset and lead to an initial diagnosis of schizophrenia 
(Galimberti et  al., 2014a), bipolar disorder (Galimberti et  al., 
2014b), obsessive–compulsive disorder (Calvo et  al., 2012), 
depressive pseudodementia (Bieniek et  al., 2014), or DLB 
(Robinson et al., 2014).
Mutations in C9orf72 have been rarely observed in patients 
with PPA (Renton et al., 2011; Dobson-Stone et al., 2012; Englund 
et al., 2012; Mahoney et al., 2012; Sha et al., 2012; Simon-Sanchez 
et al., 2012; Snowden et al., 2012; Van Langenhove et al., 2013; 
Saint-Aubert et al., 2014).
As in GRN and MAPT mutations, deficits in episodic memory 
at onset, mimicking AD have been reported also in patients 
with C9orf72 mutations (Wojtas et al., 2012; Cacace et al., 2013; 
Harms et al., 2013; Murray et al., 2013; Pletnikova et al., 2014). 
Moreover, extrapyramidal movement disorder (usually an 
akinetic-rigid syndrome) (Murray et al., 2011; Boeve et al., 2012; 
Cooper-Knock et al., 2012; Floris et al., 2012; Hsiung et al., 2012; 
Simon-Sanchez et al., 2012) and cerebellar signs have also been 
reported (Hsiung et al., 2012). Most patients, during the course 
of the disease, eventually develop some abnormalities of behavior, 
language, and motor function (Boeve, 2011; Byrne et  al., 2012; 
Cooper-Knock et al., 2012; Hsiung et al., 2012; Stewart et al., 2012).
Structural neuroimaging in patients with C9orf72 expan-
sions does not reveal a characteristic pattern of atrophy, unlike 
GRN or MAPT mutations. A prevalently symmetrical, bilateral, 
cortical, and subcortical atrophy, predominantly affecting the 
frontotemporal regions, has been observed (Boeve et  al., 2012; 
Dobson-Stone et al., 2012; Englund et al., 2012; Mahoney et al., 
2012; Sha et al., 2012; Snowden et al., 2012; Whitwell et al., 2012; 
Devenney et al., 2014).
Neuroimaging studies using VBM analysis have observed 
extensive atrophy of the frontal, insular, temporal, and parietal 
cortical and subcortical regions, including prominent atrophy 
of the thalamus and cerebellum (Mahoney et al., 2012; Whitwell 
et al., 2012; Irwin et al., 2013).
Concordant with gray matter atrophy, WM atrophy of long 
intrahemispheric, commissural, and corticospinal tracts has been 
observed with diffusion tractography (Mahoney et al., 2012).
As with structural neuroimaging, functional neuroimaging 
using FDG-PET and SPECT has shown frontal, temporal, and 
parietal cortical and subcortical alterations (Boeve et  al., 2012; 
Adeli et al., 2014; Suárez-Calvet et al., 2014). Seed-based intrinsic 
connectivity analyses in C9orf72 carriers versus non-carriers 
showed connectivity reductions in the salience and sensorimotor 
networks, with severity of behavioral symptom correlating with 
diminished salience network connectivity and increased DMN 
connectivity (Lee et al., 2014).
As in GRN and MAPT mutations, presymptomatic imaging 
signatures can be identified in asymptomatic adults at risk of 
genetic FTD. Rohrer et al. observed differences, between C9orf72 
mutation carriers and non-carriers, in subcortical areas, includ-
ing the thalamus, the insula, and posterior cortical areas 25 years 
before expected onset, followed by the frontal and temporal lobes 
20 years before expected onset, and in the cerebellum 10 years 
before expected onset (Rohrer et al., 2015b).
VCP Mutations
Missense mutations in the VCP gene, located on chromosome 
9p13.3, were originally reported in 2004 in North American fami-
lies with a specific autosomal dominant multisystem syndrome 
called inclusion body myopathy with Paget disease of bone and/
or FTD (IBMPFD) (Watts et al., 2004), with neuropathology con-
sistent with type D TDP-43 pathology (van der Zee et al., 2009).
Valosin-containing protein, also known as p97, is a mem-
ber of the ATPases associated with various cellular activities 
(AAA) family of proteins and is involved in multiple cellular 
processes, including protein degradation via both proteasome 
and autophagy pathways, in membrane fusion, transcriptional 
activation, apoptosis, and molecular chaperoning (Nalbandian 
et al., 2011; Yamanaka et al., 2012). The role of mutant VCP in 
the pathogenesis of IBMPFD or FTD-ALS remains elusive.
So far, 19 pathogenic mutations in VCP have been described 
(Cruts et al., 2012). The frequency of VCP mutations in FTD is 
about 1.6%, making it a rare but significant cause of FTD (van 
der Zee et al., 2009). Nearly 80% of VCP mutation carriers have 
a positive family history with a wide variability in phenotypic 
presentation, even within the same family.
The disease usually begins at the age of 40 with musculoskel-
etal symptoms not dissimilar to limb-girdle muscular dystrophy, 
affecting more than 80% patients. Moreover, nearly 60% patients 
develop adult-onset Paget disease of bone (Watts et al., 2004). FTD 
usually develops later on in the disease course (age 55–60 years), 
affecting about 30% of patients, with a classical bvFTD pheno-
type (Kovach et al., 2001; Guyant-Marechal et al., 2006; Kimonis 
et al., 2008); occasional psychiatric disorders have been reported 
(Jacquin et  al., 2013). However, although rare, VCP mutations 
have been found in patients with a dementia-only phenotype 
(van der Zee et al., 2009). Early language deficits and semantic 
impairment have been rarely described (Kim et al., 2011).
VCP mutations have been identified also in patients with 
an MND/ALS phenotype, occasionally associated with FTD 
(Johnson et al., 2010; Miller et al., 2012; Hirano et al., 2015); these 
findings are supported by the pyramidal tract dysfunction which 
has been observed in some cases (Kumar et al., 2010).
The term multisystem proteinopathy has been recently pro-
posed to replace the term IBMPFD to describe this phenotype 
(Benatar et al., 2013).
MRI findings range widely, from cases showing no signs of 
frontal lobe atrophy to patients with prominent, asymmetric, focal 
atrophy in the anterior and temporal lobes (Gidaro et al., 2008; 
Djamshidian et al., 2009; Stojkovic et al., 2009; Kim et al., 2011; 
Surampalli et al., 2015). FDG-PET imaging has revealed severe 
glucose hypometabolism in the bilateral frontotemporoparietal 
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areas (Guyant-Marechal et al., 2006; Stojkovic et al., 2009; Kim 
et al., 2011).
TARDBP Mutations
Transactive response DNA-binding protein 43 (TDP-43) is a 
ubiquitously expressed and highly conserved ribonucleoprotein, 
encoded by the TARDBP gene on chromosome 1, with a putative 
role in the regulation of transcriptional activity, of messenger 
RNA splicing, exon skipping, and microRNA biogenesis of several 
genes. It has been proposed that, in neurodegenerative disorders, 
TDP-43 can be redistributed from the nucleus to the cytoplasm 
and sequestered into inclusions that are mainly composed of 
abnormally phosphorylated and C-terminally truncated TDP-43 
fragments (Buratti and Baralle, 2008; Polymenidou et al., 2011; 
Tollervey et al., 2011).
The identification of mutations within the TARDBP gene as 
causative for both familial and sporadic ALS provided additional 
proofs for the pathogenic role of TDP-43 in neurodegeneration 
(Kabashi et al., 2008; Rutherford et al., 2008; Sreedharan et al., 
2008; Van Deerlin et al., 2008).
Mutations in the TARDBP gene were initially described in 
2008 in patients with ALS, both in familial and sporadic cases 
(Kabashi et al., 2008; Sreedharan et al., 2008; Van Deerlin et al., 
2008). So far, mutations in the TARDBP gene account for 2–3% 
of ALS patients (Gitcho et al., 2008; Kabashi et al., 2008; Kühnlein 
et al., 2008; Rutherford et al., 2008; Sreedharan et al., 2008; Van 
Deerlin et al., 2008; Yokoseki et al., 2008; Daoud et al., 2009).
Although previous studies failed to identify a significant role 
for TARDBP mutations in FTD (Rollinson et al., 2007; Gallone 
et  al., 2009; Gijselinck et  al., 2009; Schumacher et  al., 2009), 
recently it has been reported that TARDBP mutations might be 
causative of FTD with MDN. These uncommon cases present 
with a heterogeneous phenotype, almost always associated 
with a significant motor neuron involvement, including FTD-
MND (Benajiba et al., 2009; Chiò et al., 2010), FTD-MND with 
extrapyramidal symptoms (Borghero et  al., 2011; Chiò et  al., 
2011; Quadri et  al., 2011; Mosca et  al., 2012), and MND with 
supranuclear palsy (Kovacs et  al., 2009; Borghero et  al., 2011). 
Pure FTD cases without motor neuron involvement carrying a 
TARDBP mutation are even more exceptional. Indeed, less than 
16 cases have been reported so far (Borroni et  al., 2009, 2010; 
Gitcho et al., 2009; Kovacs et al., 2009; Gelpi et al., 2014; Synofzik 
et  al., 2014; Moreno et  al., 2015), with only four cases having 
neuropathological confirmation (Gitcho et al., 2009; Kovacs et al., 
2009; Gelpi et al., 2014; Moreno et al., 2015). The most common 
phenotype that was described was bvFTD followed by PPA, in 
particular with svPPA, with a heterogeneous age of onset, ranging 
from 29 to 77 years.
Neuroimaging studies, achieved only in case reports and small 
series, show predominant temporal lobe involvement (Borroni 
et al., 2009, 2010; Gitcho et al., 2009; Kovacs et al., 2009; Gelpi 
et al., 2014; Synofzik et al., 2014; Moreno et al., 2015).
TDP-43 inclusions, as previously outlined, have been observed 
also in non-TARDBP-associated genetic forms of FTLD, includ-
ing GRN, VCP, and C9orf72 mutations, suggesting that dys-
regulation of TDP-43 might be a pivotal downstream pathogenic 
mechanism involved in neurodegeneration in each of these 
disorders (Rademakers et al., 2012).
CHMP2B Mutations
The CHMP2B gene, located on chromosome 3p11.2, encodes the 
charged multivesicular body protein 2B, which has been identified 
in 2005 in a large Danish family with an autosomal form of FTLD 
(Skibinski et  al., 2005), first described in 1987 (Gydesen et  al., 
1987). The average age of onset in this family was 55 years, ranging 
from 46 to 65 years. Since 2005, researchers identified CHMP2B 
missense variants in FTD and FTD-ALS cases, representing less 
than 1% of familial forms of FTLD, although the pathogenicity 
of these variants remain to be elucidated (Parkinson et al., 2006; 
Cox et al., 2010).
The phenotypic expression of the originally described family 
comprises bvFTD that may be associated with late parkinsonism, 
dystonia, myoclonus, and pyramidal symptoms (Skibinski et al., 
2005).
Neuropathological examination revealed ubiquitin/p62-posi-
tive, TDP-43/FUS negative neuronal inclusions, termed FTLD-U 
(Holm et al., 2007, 2009).
FUS Mutations
The genetic heterogeneity of FTD is further emphasized by the 
occurrence of rare mutations in the FUS gene, located on chro-
mosome 16, which was first identified as a fusion oncogene in 
human liposarcomas (Crozat et al., 1993; Rabbitts et al., 1993).
FUS, as TAF-15 and EWS, belongs to the FET family of DNA/
RNA-binding proteins, which are highly conserved, ubiquitously 
expressed, multifunctional binding proteins (Tan and Manley, 
2009) that can bind to a large number of overlapping RNA targets 
(Hoell et al., 2011). Although the precise physiological function of 
FUS has not been fully elucidated, growing evidence suggests that 
the protein is involved in various cellular processes, including cell 
proliferation, DNA repair, transcription regulation, and multiple 
levels of RNA and microRNA processing (Lagier-Tourenne et al., 
2010; Deng et al., 2014).
In 2009, FUS gene mutations were identified as the primary 
disease-associated gene for familial (Kwiatkowski et  al., 2009; 
Vance et  al., 2009; Doi et  al., 2010) and sporadic ALS (Belzil 
et al., 2009). This mutation accounted for nearly 3% of familial 
ALS cases, characterized by FUS-positive, TDP-43 negative 
inclusions (Kwiatkowski et al., 2009; Vance et al., 2009), conse-
quently termed ALS-FUS. Eventually, FUS was found to be the 
most characteristic marker of the remaining tau-negative and/
or TDP-43 negative FTLD cases, encompassing three closely 
related but distinct clinicopathological entities: atypical FTLD-U 
(aFTLD-U), neuronal intermediate filament inclusion disease 
(NIFID), and basophilic inclusion body disease (BIBD) (Munoz 
et al., 2009; Neumann et al., 2009a,b; Urwin et al., 2010).
FUS mutations in patients with clinical FTLD are rare, and only 
four FUS mutations have so far been identified in patients with 
FTD-MND/ALS or in their families (Ticozzi et al., 2009; Blair et al., 
2010; Broustal et al., 2010; Yan et al., 2010). Moreover, two cases 
with a pure FTD phenotype without motor neuron involvement 
September 2015 | Volume 7 | Article 1719
Benussi et al. Phenotypes in FTD
Frontiers in Aging Neuroscience | www.frontiersin.org
have also been reported (Van Langenhove et al., 2010; Huey et al., 
2012). Nevertheless, no autopsy data are yet available to confirm 
FUS pathology in any patient with FTLD and FUS mutations.
In contrast to ALS with FUS pathology, which is mostly caused 
by FUS mutations, FTLD-FUS tends to be sporadic, with none yet 
associated with a mutation in the FUS gene (Rademakers et al., 
2012).
Different pathogenic mechanisms in ALS-FUS and FTLD-
FUS also arise from a recent study in which, in ALS-FUS, no 
co-accumulation of other FET-proteins into FUS-positive inclu-
sions was found, in remarkable contrast to FTLD-FUS, in which 
TAF-15 and EWS were found to co-accumulate in FUS-positive 
cytoplasmic inclusions (Neumann et al., 2011).
Structural neuroimaging studies show predominant volume 
loss in the anterior temporal lobe, amygdala, anterior hip-
pocampus, anterior insula, and anterior cingulate cortex (Lee 
et al., 2012). Bilateral anterior striatal atrophy is particularly 
prominent in the head of the caudate nucleus, which appears to 
be significantly greater in FTLD-FUS compared with FTLD-TDP 
and FTLD-tau, suggesting that severe caudate atrophy may be a 
useful clinical feature to predict FTLD-FUS pathology (Josephs 
et al., 2010; Lee et al., 2012).
Other Genetic Causes: DCTN1 and 
TREM2
There are few reports of DCTN1 mutations in patients with 
FDT and MND/ALS (Münch et al., 2005; Newsway et al., 2010), 
variably associated with parkinsonism, hypoventilation, dysau-
tonomia, weight loss, and behavioral disturbances configuring 
the recently described Perry syndrome, which is associated with 
TDP-43 pathology (Farrer et  al., 2009; Ohshima et  al., 2010). 
Notwithstanding, no mutations were found in large FTD or MND/
ALS cohorts (Seelaar et al., 2008; Vilariño-Güell et al., 2009).
Homozygous loss-of-function mutations in TREM2 on 
chromosome 6p21, encoding the triggering receptor expressed 
on myeloid cells 2 protein, have been initially associated with an 
autosomal recessive form of early onset dementia presenting with 
bone cysts and consequent fractures called polycystic lipomem-
branous osteodysplasia with sclerosing leukoencephalopathy, 
also known as Nasu-Hakola disease (Paloneva et al., 2000, 2002).
In 2013, two studies identified a rare heterozygous variant 
(R47H) on the second exon of TREM2, showing an approximately 
three- to fivefold increased risk in late onset AD (Guerreiro et al., 
2013c; Jonsson et  al., 2013). Furthermore, homozygous and 
compound heterozygous TREM2 exon 2 mutations were identi-
fied in rare families presenting with autosomal recessive bvFTD 
without any clinical or radiological evidence of bone involvement 
(Giraldo et  al., 2013; Guerreiro, 2013; Guerreiro et  al., 2013a; 
Lattante et al., 2013; Rayaprolu et al., 2013; Le Ber et al., 2014). 
Patients typically have very young age at onset (20–50 years) and, 
in addition to behavioral changes, they present with early parietal 
and hippocampal deficits, extrapyramidal features, and seizures. 
Neuroimaging frequently shows frontotemporal atrophy and 
extensive WM abnormalities (Guerreiro, 2013; Le Ber et al., 2014).
Recently, Borroni and colleagues evaluated the frequency of 
heterozygous TREM2 mutations as risk factor in FTD patients, 
confirming that the Q33X, R47H, and T66M mutations were 
significantly associated with the disease and absent in healthy 
subjects (Borroni et  al., 2013), in line with further reports 
(Cuyvers et al., 2013).
Conclusion
The striking clinical, genetic, and pathological heterogeneity 
are undisputable features of FTLD. The clinical phenotypes 
range from social to language impairment, variably associated 
with MND/ALS or extrapyramidal symptoms (see Table 1). In 
the past 9  years, considerable progress has been made toward 
unraveling the genetic causes of FTLD, with apparently all com-
mon FTD-related genes discovered, comprising C9orf72, MAPT, 
GRN, TARDBP, VCP, CHMP2B, and FUS, currently identifying 
50–60% of the familial forms of FTD, although rare mutations 
in other genes could explain a small number of the remaining 
families (Rademakers et al., 2012; Le Ber, 2013).
Neuropathology is variably associated with two predominant 
hallmarks, namely FTLD-tau (found in MAPT mutations) and 
FTLD-TDP (found in GRN, C9orf72, TARDPB, and VCP muta-
tions), although it is occasionally associated with FTLD-FUS 
(found in FUS mutations only in MND/ALS), FTLD-U (found 
in CHMP2B mutations) and the newly identified FTLD-DPR in 
C9orf72 mutations.
Why different genes linked to different molecular pathways are 
responsible for a neurodegenerative process involving mainly the 
frontotemporal lobes is still a matter for debate, and the shared 
mechanisms that lead to predominant frontal and temporal 
degeneration remain to be identified.
As previously outlined, frequently there is poor corre-
spondence between the type of mutation or neuropathological 
feature and the clinical phenotype; indeed, neuropathology is 
TABLe 1 | Main clinical presentation in monogenic FTLD.
Gene Main clinical presentation
bvFTD avPPA svPPA PSP/CBS MND/ALS
GRN +++ +++ − ++a −
MAPT ++ + − ++ −
C9orf72 +++ ++ + + +++
VCP + − − − +
TARDBP + − + − ++
CHMP2B + − − + +
FUS + − − − ++
DCTN1 − − − + +
TREM2 + − − + −
Semi-quantitive grading: +++, very frequent; ++, frequent; +, infrequent; −, sporadic 
cases or no cases reported.
GRN, progranulin; MAPT, microtubule-associated protein tau; C9orf72, chromosome 9 
open reading frame 72; VCP, valosin-containing protein; TARDBP, transactive response 
DNA-binding protein 43, CHMP2B, charged multivesicular body protein 2B; FUS, 
fused in sarcoma; DCTN1, dynactin; TREM2, triggering receptor expressed on myeloid 
cells; bvFTD, behavioral variant of frontotemporal dementia; avPPA, agrammatic 
variant of primary progressive aphasia; svPPA, semantic variant of primary progressive 
aphasia; PSP/CBS, progressive supranuclear palsy/corticobasal syndrome features; 
MND/ALS, motor neuron disease/amyotrophic lateral sclerosis.
aCBS presentation only.
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predicable only in known genetic defects and few clinical or 
neuroanatomical features have a specific molecular association 
(Rohrer et al., 2011a). Both clinically and anatomically, differ-
ent genetic mutations show substantial overlap between dis-
eases. However, certain distinctive clinical and neuroimaging 
features emerge and might help in driving neurology practice 
in molecular diagnostics. Patients with C9orf72 repeat expan-
sion usually have an early disease onset and a family history 
of FTD (mainly bvFTD with disinhibition or svPPA), which is 
variably associated with MND/ALS. MAPT mutation carriers 
often present with a very early age of onset bvFTD, associated 
with parkinsonism, which is a common feature later in the 
disease course in all types of genetic FTLD. GRN mutations 
carriers frequently present with bvFTD, avPPA, and concomi-
tant CBS at onset. TARDBP sequencing should be performed 
in familial or sporadic C9orf72 negative FTD-MND/ALS cases. 
The association of inclusion body myopathy and Paget’s disease 
are indicative of VCP mutations (Rohrer and Warren, 2011; 
Borroni and Padovani, 2013; Le Ber, 2013; Van Langenhove 
et al., 2013).
In addition to these distinct clinical features, from a neuroimag-
ing perspective, strikingly asymmetric interhemispheric atrophy 
with frontoparietal involvement is indicative of GRN mutations, 
while relative symmetric atrophy with particular involvement 
of the anterior temporal lobes is indicative of MAPT mutations 
(Rohrer et al., 2010b; Whitwell et al., 2012). On the other hand, 
C9orf72 mutation carriers tend to have a more generalized and 
symmetrical atrophy (Rohrer et al., 2010b; Whitwell et al., 2012; 
Van Langenhove et al., 2013) (see Table 2).
Numerous attempts have been made to identify an in vivo bio-
marker that can accurately predict the underlying neuropathol-
ogy and consequently point out which gene should be analyzed, 
but a clear-cut association between clinical or neuroradiological 
features and characteristic histological inclusions has not been 
yet established (Kim et al., 2007; Josephs et al., 2008; McMillan 
et al., 2013). Plasma progranulin levels have been shown to be 
reliable predictors of GRN mutations, and should be performed 
before GRN sequencing (Finch et al., 2009; Ghidoni et al., 2012). 
Furthermore, the recently identified cerebrospinal phospho-
tau181 to total-tau ratio appears to predict FTLD-TDP pathology 
with high accuracy, thus leading to the search of genes associated 
with TDP-43 neuropathology (Hu et al., 2013; Grossman et al., 
2014; Borroni et al., 2015a).
Considering the vast clinical, genetic, and pathological hetero-
geneity associated with this disease, the development of accurate 
in vivo biomarkers is mandatory for guiding genetic screening, 
for defining distinctive therapeutic approaches and helping in 
patients’ selection in future clinical trials.
TABLe 2 | Preclinical and clinical neuroanatomical correlates in monogenic FTLD.
Gene Severity of atrophy in preclinical/clinical phase
FL TL PL iN HC ST
GRN +/+++ +/++ +/++ ++/+ −/− −/−
MAPT −/++ ++/+++ −/− +/+++ ++/+++ −/+++
C9orf72 +++/+++ ++/+++ ++/++ +++/+++ +++/+++ −/−
VCP −/++ −/++ −/+ −/− −/++ −/−
TARDBP −/+ −/++ −/+ −/+ −/− −/−
CHMP2B +/+ +/++ +/+ +/+ −/− −/−
FUS −/++ −/++ −/++ −/− −/− −/+++
DCTN1 −/++ −/++ −/+ −/+ −/++ −/−
TREM2 −/++ −/+ −/++ −/− −/+ −/+
Semi-quantitive grading: +++, severe; ++, moderate; +, mild; −, absent or not reported.
FL, frontal lobe; TL, temporal lobe; PL, parietal lobe; IN, insula; HC, hippocampus; ST, striatum; GRN, progranulin; MAPT, microtubule-associated protein tau; C9orf72, chromosome 
9 open reading frame 72; VCP, valosin-containing protein; TARDBP, transactive response DNA-binding protein 43; CHMP2B, charged multivesicular body protein 2B; FUS, fused in 
sarcoma; DCTN1, dynactin; TREM2, triggering receptor expressed on myeloid cells.
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